Skip to content

Study of Shigru Pallava Eye Drops and Shigru Nanocapsules Along with Standard of Care to Improve Non proliferative Diabetic Retinopathy

A Four Arm Randomized Controlled Clinical Trial to Evaluate the Efficacy of Shigru Pallava Eye Drops Shigru Nanocapsules and Their Combination as Add on Treatment to Standard of Care in Patients with Non Proliferative Diabetic Retinopathy NPDR - Nil

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/07/113799
Enrollment
108
Registered
2026-07-09
Start date
Unknown
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E113- Type 2 diabetes mellitus with ophthalmic complications

Interventions

None listed

Sponsors

Parul Institute of Ayurved Parul University
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Subjects diagnosed with Diabetes Mellitus at least 10yr of History Patients diagnosed with mild to severe non proliferative diabetic retinopathy only one eye were selected in that only lower severity was selected if both eye were equal RE was selected Subject having HbA1c in the range of 6 to 9

Exclusion criteria

Exclusion criteria: Patients with other types of retinal diseases Patients who had undergone ocular surgery in the study eye 6month prior to the study pregnant diabetic patients Patients taking with any other treatment for diabetic retinopathy Patients with cardiovascular problems Uncontrolled hypertensive patients with systolic above 170 and diastolic above 100 Who had history of adverse reaction to Herbo mineral preparations Subject having history of consumption of corticosteroids or 3months prior to the study

Design outcomes

Primary

MeasureTime frame
Change in severity of Non proliferative Diabetic Retinopathy Assessed by Fundus Examination and Optical Coherence TomographyTimepoint: Baseline and at the end of 3 month

Secondary

MeasureTime frame
Change in Best Corrected Visual Acuity Change in HbA1c levels Safety and tolerability assessedTimepoint: Baseline and at the end of 3 month

Countries

India

Contacts

Public ContactMiral Patel

Parul Institute of Ayurved

manjiri.keskar26993@paruluniversity.ac.in9822606358

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Aug 10, 2026